Overall demand for digestive remedies has moderately decreased on account of COVID-19, with value sales among all categories predicted to decline or decelerate in 2020 as a whole compared with their performances in the previous year (pre-pandemic). Value sales of travel-related products such as diarrhoeal remedies and motion sickness remedies have decreased in light of the country’s lockdown and ongoing travel restrictions, while indigestion and heartburn remedies is mostly stagnant, due to people being on the go less given the widespread closure of workplaces and also because eating out has become much less common.
H2 blockers is posting by far the biggest sales decline in 2020, having decreased strongly in the previous year too. This is because the Finnish Medicines Agency, Fimea, banned sales of ranitidine in September 2019 due to possible contamination of this active substance with NDMA (N-nitrosodimethylamine), an impurity which has been identified as a risk factor in the development of certain cancers.
International players continue to lead digestive remedies in 2020, with Takeda Oy and Janssen-Cilag Oy competing closely with their respective well-established laxative brands Levolac, Microlax, and Vi-Siblin, while Janssen-Cilag is also present in diarrhoeal remedies with Imodium. However, over most of the review period both players continued to lose value share to companies such as Orion Oyj, Mylan Finland Oy and Biocodex SAS which are slowly gaining ground.
With travel restrictions easing and restaurants and other food establishments now reopen for dine-in, the sales performance of digestive remedies has been allowed to improve since the lockdown was lifted in mid-May. The rich food and drink consumed at Christmas time is very likely to boost sales, and the category is predicted to bounce back in 2021, with most product types performing stronger, provided there are no further lockdowns.
Laxatives is set to remain the largest category by 2025 and will post among the highest value growth rates over the forecast period. It has a wide range of brands available led by Takeda’s Levolac.
From a small sales base, paediatric laxatives is poised to record the second-biggest value sales CAGR, after digestive enzymes, thanks to an expansion in the product range and greater consumer-awareness. Within this niche category, second-ranked Mylan Finland Oy has continued to gain strong value share from leader Takeda Oy, due to the ongoing double-digit current value growth of its Duphagol Junior brand.
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
Understand the latest market trends and future growth opportunities for the Digestive Remedies industry in Finland with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Digestive Remedies industry in Finland, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
This report originates from Passport, our Digestive Remedies research and analysis database.
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE! Home Page